A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report - Ni, Junjun; Yang, Liangwei; Zhu, Huangkai; Chu, Minghui; Zhang, Chenxu; Zhao, Weidi; Yang, Minglei; Xu, Xiang; Zheng, Enkuo; Jiang, Xu; Li, Rui; Zhao, Guofang (Annals of Palliative Medicine; Vol 10, No 4 (April 30, 2021): Annals of Palliative Medicine, 2021)